These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28115268)

  • 1. Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: Data from the French registry REGATE.
    Terreaux W; Masson C; Eschard JP; Bardin T; Constantin A; Le Dantec L; Marcelli C; Perdriger A; Scotto Di Fazano C; Wendling D; Sibilia J; Morel J; Salmon JH
    Joint Bone Spine; 2018 Jan; 85(1):53-57. PubMed ID: 28115268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE.
    Morel J; Constantin A; Baron G; Dernis E; Flipo RM; Rist S; Combe B; Gottenberg JE; Schaeverbeke T; Soubrier M; Vittecoq O; Dougados M; Saraux A; Mariette X; Ravaud P; Sibilia J
    Rheumatology (Oxford); 2017 Oct; 56(10):1746-1754. PubMed ID: 28957557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.
    Salmon JH; Perotin JM; Morel J; Dramé M; Cantagrel A; Ziegler LE; Ravaud P; Sibilia J; Pane I; Mariette X; Gottenberg JE;
    Rheumatology (Oxford); 2018 Jan; 57(1):134-139. PubMed ID: 29069471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.
    Gottenberg JE; Morel J; Perrodeau E; Bardin T; Combe B; Dougados M; Flipo RM; Saraux A; Schaeverbeke T; Sibilia J; Soubrier M; Vittecoq O; Baron G; Constantin A; Ravaud P; Mariette X;
    BMJ; 2019 Jan; 364():l67. PubMed ID: 30679233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of surgery in patients with rheumatoid arthritis treated with tocilizumab: data from the French (REGistry -RoAcTEmra) Regate registry.
    Morel J; Locci M; Banal F; Combe B; Cormier G; Dougados M; Flipo RM; Marcelli C; Pham T; Rist S; Solau Gervais E; Sibilia J; Lukas C
    Clin Exp Rheumatol; 2020; 38(3):405-410. PubMed ID: 31969215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular events and change in cholesterol levels in patients with rheumatoid arthritis treated with tocilizumab: data from the REGATE Registry.
    Lukas C; Redondin M; Pane I; Soubrier M; Houvenagel E; Sibilia J; Combe B; Morel J
    Clin Exp Rheumatol; 2021; 39(3):501-507. PubMed ID: 32896267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.
    Sakai R; Tanaka M; Nanki T; Watanabe K; Yamazaki H; Koike R; Nagasawa H; Amano K; Saito K; Tanaka Y; Ito S; Sumida T; Ihata A; Ishigatsubo Y; Atsumi T; Koike T; Nakajima A; Tamura N; Fujii T; Dobashi H; Tohma S; Sugihara T; Ueki Y; Hashiramoto A; Kawakami A; Hagino N; Miyasaka N; Harigai M;
    Ann Rheum Dis; 2012 Nov; 71(11):1820-6. PubMed ID: 22504558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany.
    Iking-Konert C; von Hinüber U; Richter C; Schwenke H; Gürtler I; Kästner P; Klapperich B; Peters MA; Burmester GR
    Rheumatology (Oxford); 2016 Apr; 55(4):624-35. PubMed ID: 26515959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.
    Sakai R; Cho SK; Nanki T; Watanabe K; Yamazaki H; Tanaka M; Koike R; Tanaka Y; Saito K; Hirata S; Amano K; Nagasawa H; Sumida T; Hayashi T; Sugihara T; Dobashi H; Yasuda S; Sawada T; Ezawa K; Ueda A; Fujii T; Migita K; Miyasaka N; Harigai M;
    Arthritis Res Ther; 2015 Mar; 17(1):74. PubMed ID: 25880658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AA amyloidosis treated with tocilizumab: case series and updated literature review.
    Courties A; Grateau G; Philippe P; Flipo RM; Astudillo L; Aubry-Rozier B; Fabreguet I; Fahd W; Fain O; Guggenbuhl P; Hachulla E; Papo T; Richez C; Sibilia J; Morel J; Berenbaum F; Sellam J;
    Amyloid; 2015; 22(2):84-92. PubMed ID: 25585627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.
    Grøn KL; Arkema EV; Glintborg B; Mehnert F; Østergaard M; Dreyer L; Nørgaard M; Krogh NS; Askling J; Hetland ML;
    Ann Rheum Dis; 2019 Mar; 78(3):320-327. PubMed ID: 30612115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan.
    Cho SK; Sakai R; Nanki T; Koike R; Watanabe K; Yamazaki H; Nagasawa H; Tanaka Y; Nakajima A; Yasuda S; Ihata A; Ezawa K; Won S; Choi CB; Sung YK; Kim TH; Jun JB; Yoo DH; Miyasaka N; Bae SC; Harigai M; ;
    Mod Rheumatol; 2014 Jul; 24(4):572-9. PubMed ID: 24320747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.
    Iannone F; Ferraccioli G; Sinigaglia L; Favalli EG; Sarzi-Puttini P; Atzeni F; Gorla R; Bazzani C; Govoni M; Farina I; Gremese E; Carletto A; Giollo A; Galeazzi M; Foti R; Bianchino L; La Grasta L; Lapadula G
    Clin Rheumatol; 2018 Feb; 37(2):315-321. PubMed ID: 28980085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doubling the single-dose infusion rate of tocilizumab in rheumatoid arthritis is safe and efficacious.
    Lindegaard HM; Johansen P; Gröndal G; Jensen EC; Juul L; Schlemmer AM; Agular B; Hansen I
    Scand J Rheumatol; 2016 Jul; 45(4):262-6. PubMed ID: 26727655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study.
    Gossec L; Steinberg G; Rouanet S; Combe B
    Clin Exp Rheumatol; 2015; 33(5):664-70. PubMed ID: 26344671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.
    Mariette X; Gottenberg JE; Ravaud P; Combe B
    Rheumatology (Oxford); 2011 Jan; 50(1):222-9. PubMed ID: 21148156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Rutherford AI; Subesinghe S; Hyrich KL; Galloway JB
    Ann Rheum Dis; 2018 Jun; 77(6):905-910. PubMed ID: 29592917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
    Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac Tamponade During Tocilizumab Therapy in a Patient with Rheumatoid Arthritis and Anti-DNA Antibody Positivity.
    Miyahara D; Moriyama Y; Yamazaki Y; Tanii H; Okano Y; Sakurada H
    Intern Med; 2021 Oct; 60(20):3245-3249. PubMed ID: 33776015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.